What is AutoGen?
Headquartered in Holliston, Massachusetts, AutoGen occupies a critical niche within the biotechnology supply chain. The company specializes in the development and distribution of high-performance nucleic acid extraction equipment, serving as a vital partner to research institutions and clinical laboratories. By maintaining proximity to the Boston biotech hub, AutoGen effectively integrates into the broader life science ecosystem, providing value-added solutions that streamline complex sample preparation processes. Their market position is defined by a commitment to technical precision and the delivery of reliable, scalable instrumentation essential for modern genomic analysis.
How much funding has AutoGen raised?
AutoGen has raised a total of $412K across 2 funding rounds:
Debt
$150K
Debt
$262K
Debt (2020): $150K with participation from PPP
Debt (2021): $262K led by PPP
Key Investors in AutoGen
PPP
Public-Private Partnership
What's next for AutoGen?
With the successful completion of this late-stage financing, AutoGen is well-positioned to accelerate its growth trajectory and enhance its product development pipeline. The strategic allocation of this capital will likely focus on scaling manufacturing capabilities and expanding market reach to meet the increasing demand for high-throughput sample processing. As the life sciences industry continues to prioritize automation and efficiency, AutoGen's focus on specialized extraction technology provides a clear competitive advantage. Future initiatives will likely involve deepening their integration into clinical diagnostic environments, further cementing their role as an indispensable supplier in the global research and development landscape.
See full AutoGen company page
